- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work | 2 | Seeking Alpha | ||
| 14.05. | Valion Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Valion Bio subsidiary secures exclusive NMR platform license | 1 | Investing.com | ||
| 14.05. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Valion Bio, Inc.: Valion Bio Reports First Quarter 2026 Financial Results | 137 | PR Newswire | First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity... ► Artikel lesen | |
| VALION BIO Aktie jetzt für 0€ handeln | |||||
| 05.05. | Valion Bio receives protocol for radiation syndrome drug study | 3 | Investing.com | ||
| 05.05. | Tivic Health Systems, Inc.: Valion Bio Receives First FDA-precedent Study Protocol From Niaid For Entolimod; Federal Agency To Fully Fund Bla-enabling In Vivo Program And Co-navigate FDA Submission | 154 | PR Newswire | Initial Study to Evaluate Entolimod for Gastrointestinal Tissue Preservation in Partial-Body Acute Radiation Syndrome - an Indication for Which No Currently Approved... ► Artikel lesen | |
| 04.05. | Valion Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.04. | Tivic Health Systems Rebrands to Valion Bio | 2 | Contract Pharma | ||
| 24.04. | Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening | 2 | Benzinga.com | ||
| 23.04. | Tivic Health Systems, Inc.: Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model | 183 | PR Newswire | Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod Toward BARDA Funding and Strategic National Stockpile Procurement... ► Artikel lesen | |
| 23.04. | Tivic Health Systems, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.04. | Tivic Health Systems, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 31.03. | Tivic Health receives Ukraine request for radiation treatment | 6 | Investing.com | ||
| 31.03. | Tivic Health Systems: Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod | 350 | ACCESS Newswire | SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it has received a formal Request for Information... ► Artikel lesen | |
| 27.03. | Tivic Health Systems: Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference | 637 | ACCESS Newswire | Presentation will Cover Recent Corporate Milestones Including Securing Agreement with NIAID SAN ANTONIO, TX / ACCESS Newswire / March 27, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage... ► Artikel lesen | |
| 26.03. | Tivic Health Systems: Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome | 524 | ACCESS Newswire | Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study SAN ANTONIO, TX / ACCESS Newswire / March 26, 2026 / Tivic Health Systems... ► Artikel lesen | |
| 26.03. | Tivic Health Systems reports FY25 results | 2 | Seeking Alpha | ||
| 25.03. | Tivic Health outlines $20B oncology market opportunity following strategic transformation | 1 | Seeking Alpha | ||
| 25.03. | Strategiewechsel bei Tivic Health: Fokus künftig auf Biopharma | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 5,440 | +10,46 % | Plus Therapeutics Inc.: Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ Clinical Program and CNSide Commercial Rollout | HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| ORGANON | 11,570 | +0,13 % | Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia | SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines... ► Artikel lesen | |
| CO-DIAGNOSTICS | 3,705 | -0,13 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| SENSEONICS | 5,150 | -2,83 % | Senseonics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| VIRIDIAN THERAPEUTICS | 15,300 | +0,66 % | Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M | ||
| INSPIRE MEDICAL SYSTEMS | 38,400 | -0,52 % | Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance | First quarter revenue growth of 1.6%First quarter diluted EPS of $(0.39); adjusted diluted EPS of $0.10First quarter operating cash flow of $12.8 million MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| VYOME | 2,230 | 0,00 % | Vyome: Positive Phase-2-Daten für Wundbehandlung bei Krebspatienten | ||
| EMBECTA | 2,850 | -0,56 % | Embecta Corp.: embecta Completes Acquisition of Owen Mumford Holdings Limited | PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,900 | -0,10 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| AXOGEN | 37,590 | +5,71 % | Axogen, Inc.: Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock | ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral... ► Artikel lesen | |
| TACTILE SYSTEMS TECHNOLOGY | 21,780 | -1,27 % | Tactile Systems Technology, Inc.: Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio | MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (Nasdaq: TCMD), a medical technology company providing therapies for people with... ► Artikel lesen | |
| APYX MEDICAL | 3,200 | -3,61 % | Apyx Medical Corp - 8-K, Current Report | ||
| GLAUKOS | 120,00 | 0,00 % | Glaukos - GKOS: Pullback-Setup mit Unterstützung bei 130 USD! | Starkes Wachstum erwartet! Aber Achtung: Insider verkaufen Glaukos-Aktien (GKOS) im Wert von 4.2 Millionen USD! Glaukos (GKOS) - US3773221029 Rückblick: Aufgrund der stark überkauften Situation am US-Gesamtmarkt... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 0,610 | +0,71 % | Lexaria Bioscience Corp.: Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 | KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics... ► Artikel lesen | |
| ITONIC | 0,294 | -2,00 % | iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule | BEIJING, China, April 23, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (the "Company" or "ITOC"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other... ► Artikel lesen |
VALION BIO INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +2,41 % bei einem Aktienkurs von 0,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALION BIO INC finden Sie auf Wallstreet Online.